Millennium Resumes Clinical Program For MLN0002
May 27th 2007Drug InformationIrritable-Bowel Syndrome
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of patient dosing in a clinical program designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MLN0002 derived from a newly engineered, commercially scaleable cell line. MLN0002 is a novel monoclonal antibody that binds to the T-cell integrin alpha 4 beta 7 with potential in a variety of gastrointestinal diseases, including ulcerative colitis. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
